Automate Your Wheel Strategy on VTYX
With Tiblio's Option Bot, you can configure your own wheel strategy including VTYX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VTYX
- Rev/Share 0.0203
- Book/Share 2.9408
- PB 0.8178
- Debt/Equity 0.0492
- CurrentRatio 19.123
- ROIC -0.5936
- MktCap 171496991.0
- FreeCF/Share -1.4855
- PFCF -1.6214
- PE -1.4386
- Debt/Assets 0.0448
- DivYield 0
- ROE -0.4889
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the following upcoming investor conferences: 2025 Wells Fargo Healthcare Conference Location: Boston, MADate: Friday, September 5, 2025Time: 11:00-11:35 AM EDT Morgan Stanley 23 rd Annual Global Healthcare Conference Location: New York, NYDate: Monday, September 8, 2025 H.C. Wainwright 27th Annual Global Investment Conference Location: New York, NYDate: Monday, September 8, 2025 A webcast of the Wells Fargo presentation will …
Read More
Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Ventyx Biosciences (VTYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958 SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that data from the Phase 2 trial of its TYK2 inhibitor VTX958 in Crohn's disease will be presented during the 20th Congress of the European Crohn's …
Read More
About Ventyx Biosciences, Inc. (VTYX)
- IPO Date 2021-10-21
- Website https://www.ventyxbio.com
- Industry Biotechnology
- CEO Raju S. Mohan
- Employees 81